SG11201910134SA - Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof - Google Patents

Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Info

Publication number
SG11201910134SA
SG11201910134SA SG11201910134SA SG11201910134SA SG 11201910134S A SG11201910134S A SG 11201910134SA SG 11201910134S A SG11201910134S A SG 11201910134SA SG 11201910134S A SG11201910134S A SG 11201910134SA
Authority
SG
Singapore
Prior art keywords
international
new jersey
antibodies
kenilworth
rule
Prior art date
Application number
Other languages
English (en)
Inventor
Soumendu Bhattacharya
Arnab De
Chakravarthy Nachu Narasimhan
Manoj Sharma
Xiaoyu Yang
Rubi Burlage
Jason Cheung
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SG11201910134SA publication Critical patent/SG11201910134SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11201910134S 2017-05-02 2018-05-01 Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof SG11201910134SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762500268P 2017-05-02 2017-05-02
PCT/US2018/030420 WO2018204343A1 (fr) 2017-05-02 2018-05-01 Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
SG11201910134SA true SG11201910134SA (en) 2019-11-28

Family

ID=64016829

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201910134S SG11201910134SA (en) 2017-05-02 2018-05-01 Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Country Status (16)

Country Link
US (1) US20200262922A1 (fr)
EP (1) EP3618866A4 (fr)
JP (2) JP2020518598A (fr)
KR (1) KR102624564B1 (fr)
CN (1) CN110678199A (fr)
AU (1) AU2018263837A1 (fr)
BR (1) BR112019022695A2 (fr)
CA (1) CA3060695A1 (fr)
CL (1) CL2019003143A1 (fr)
CO (1) CO2019012143A2 (fr)
EA (1) EA201992526A1 (fr)
MA (1) MA50501A (fr)
MX (1) MX2019013034A (fr)
SG (1) SG11201910134SA (fr)
TN (1) TN2019000294A1 (fr)
WO (1) WO2018204343A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102131828B (zh) 2007-06-18 2015-06-17 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
IL266918B2 (en) 2016-12-07 2024-03-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2019160755A1 (fr) * 2018-02-13 2019-08-22 Merck Sharp & Dohme Corp. Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4
US20210380694A1 (en) * 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
AU2020356303A1 (en) * 2019-09-23 2022-04-14 Merck Sharp & Dohme Llc Methods and compositions comprising an anti-CTLA4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability
WO2021178657A1 (fr) * 2020-03-05 2021-09-10 Merck Sharp & Dohme Corp. Méthodes de traitement du cancer à l'aide d'une combinaison d'un antagoniste de pd-1, d'un antagoniste de ctla4 et de lenvatinib ou d'un sel pharmaceutiquement acceptable associé
US20220031843A1 (en) * 2020-07-08 2022-02-03 Regeneron Pharmaceuticals, Inc. Stabilized Formulations Containing Anti-CTLA-4 Antibodies
US20220202946A1 (en) * 2020-11-10 2022-06-30 Sanofi Ceacam5 antibody-drug conjugate formulation
WO2023211868A1 (fr) * 2022-04-29 2023-11-02 Merck Sharp & Dohme Llc Formulations stables d'anticorps anti-ilt4 ou de fragments de liaison à l'antigène de ceux-ci en combinaison avec des anticorps anti-pd-1 et leurs procédés d'utilisation
WO2024025989A1 (fr) * 2022-07-28 2024-02-01 Merck Sharp & Dohme Llc Compositions pharmaceutiques d'anticorps de récepteur de mort programmée 1 (pd-1) et rhuph20 ou variants ou fragments de ceux-ci
WO2024025986A1 (fr) * 2022-07-28 2024-02-01 Merck Sharp & Dohme Llc Compositions pharmaceutiques d'anticorps de récepteur 1 de mort programmée (pd-1) et de variants de ph20 ou de fragments de ceux-ci

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2600836A1 (fr) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Compositions d'anticorps contre m-csf
EP2161336B2 (fr) * 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (PD-1) et procédés de traitement du cancer à l'aide d'anticorps anti-PD-1 seuls ou combinés à d'autres formulations immunothérapeutiques
AU2010263058A1 (en) * 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
PE20180394A1 (es) * 2015-04-17 2018-02-28 Bristol Myers Squibb Co Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
US9995753B2 (en) * 2015-09-25 2018-06-12 Merck Sharp & Dohme Corp. Anti-pembrolizumab antibodies

Also Published As

Publication number Publication date
CN110678199A (zh) 2020-01-10
EP3618866A4 (fr) 2021-07-14
KR102624564B1 (ko) 2024-01-12
TN2019000294A1 (en) 2021-05-07
MX2019013034A (es) 2020-02-05
MA50501A (fr) 2020-09-09
AU2018263837A1 (en) 2019-12-05
JP2023109942A (ja) 2023-08-08
CO2019012143A2 (es) 2020-01-17
EA201992526A1 (ru) 2020-03-13
WO2018204343A1 (fr) 2018-11-08
JP2020518598A (ja) 2020-06-25
KR20190142393A (ko) 2019-12-26
CA3060695A1 (fr) 2018-11-08
US20200262922A1 (en) 2020-08-20
EP3618866A1 (fr) 2020-03-11
BR112019022695A2 (pt) 2020-05-26
CL2019003143A1 (es) 2020-03-20

Similar Documents

Publication Publication Date Title
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201910182RA (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201909081YA (en) Anti-ilt4 antibodies and antigen-binding fragments
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201808242UA (en) Methods for inhibiting angiogenesis in a subject in need thereof
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201804765UA (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
SG11201805048SA (en) Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201900138TA (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201804178YA (en) Pd1 and/or lag3 binders
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201806496SA (en) Antigen binding proteins that bind pd-l1